Frans L Opdam

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 3

Top Topics

Histone Deacetylase

Ejection Fraction

Prognostic Factors

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

Cancer discovery

This page only lists publications with an associated author ORCID identifier.

Publications

Alaa Embaby, Sanne C F A Huijberts, Liqin Wang, Rodrigo Leite de Oliveira, Hilde Rosing, Bastiaan Nuijen, Joyce Sanders, Ingrid Hofland, Charlaine van Steenis, Roelof J C Kluin, Cor Lieftink, Christopher G Smith, Christian U Blank, Johannes V van Thienen, John B A G Haanen, Neeltje Steeghs, Frans L Opdam, Jos H Beijnen, Alwin D R Huitema, René Bernards, Jan H M Schellens, Sofie Wilgenhof
A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (15) (2024)
Alaa Embaby, Sanne C F A Huijberts, Liqin Wang, Rodrigo Leite de Oliveira, Hilde Rosing, Bastiaan Nuijen, Joyce Sanders, Ingrid Hofland, Charlaine van Steenis, Roelof J C Kluin, Cor Lieftink, Christopher G Smith, Christian U Blank, Johannes V van Thienen, John B A G Haanen, Neeltje Steeghs, Frans L Opdam, Jos H Beijnen, Alwin D R Huitema, René Bernards, Jan H M Schellens, Sofie Wilgenhof
A proof-of-concept study of sequential treatment with the HDAC inhibitor vorinostat following BRAF and MEK inhibitors in BRAFV600mutated melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Birgit Wilding, Lydia Woelflingseder, Anke Baum, Krzysztof Chylinski, Gintautas Vainorius, Neil Gibson, Irene C Waizenegger, Daniel Gerlach, Martin Augsten, Fiona Spreitzer, Yukina Shirai, Masachika Ikegami, Sylvia Tilandyova, Dirk Scharn, Mark A Pearson, Johannes Popow, Anna C Obenauf, Noboru Yamamoto, Shunsuke Kondo, Frans L Opdam, Annemarie Bruining, Shinji Kohsaka, Norbert Kraut, John Victor Heymach, Flavio Solca, Ralph A Neumuller
Zongertinib (BI 1810631), an irreversible HER2 TKI, spares EGFR signaling and improves therapeutic response in preclinical models and patients with HER2-driven cancers. Cancer discovery (2024)